UTHR · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$591.35-0.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $832.5M | $799.5M | +4.13% |
| Profit | $258.6M | $338.7M | -23.65% |
| Profit per share | $5.71 | $7.16 | -20.25% |
| Free Cash Flow | $125.8M | $351.6M | -64.22% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Therapeutics Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from United Therapeutics Corporation’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Just reported
From United Therapeutics Corporation's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$832.5M
+4.1% y/y
+6.3% q/q
Guided
—
No guide given
Actual
$5.71
-20% y/y
-21% q/q
Guided
—
No guide given
Actual
$307.8M
-21% y/y
-7.0% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
United Therapeutics Corporation reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Call summaries are part of Pro
A two-minute read of every United Therapeutics Corporation earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.